Table 3.
Laboratory data and adipose tissue area with computed tomography in patients with T2DM
| Patients with T2DM (N=148) | |
|---|---|
| Laboratory data |
|
| Creatinine, mg/dl |
0.92 ± 0.17 |
| eGFR, ml/min |
83 ± 26 |
| Triglyceride, mg/dl |
139 ± 100 |
| HDL cholesterol, mg/dl |
50 ± 15 |
| Total cholesterol, mg/dl |
198 ± 34 |
| F-LDL cholesterol, mg/dl |
119 ± 32 |
| Fasting plasma glucose, mg/dl |
138 ± 38 |
| Hemoglobin A1c, % |
7.9 ± 1.4 |
| NEFA, μEq/L |
613 ± 202 |
| IRI, μg/dl |
8.7 ± 7.0 |
| HOMA-R |
2.9 ± 2.7 |
| hsCRP, mg/dl |
0.190 ± 0.357 |
| NT-proBNP, pg/ml |
36.2 ± 55.3 |
| CPR, mg/dl |
2.8 ± 9.6 |
| Fat areas determined by CT scan |
|
| Total adipose tissue/BSA, cm2/m2 |
169.4 ± 74.9 |
| Visceral adipose tissue/BSA, cm2/m2 |
68.3 ± 30.6 |
| Subcutaneous adipose tissue/BSA, cm2/m2 | 101.1 ± 54.3 |
eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; F-LDL, low-density lipoprotein calculated by Friedewald; NEFA, non-esterified fatty acid; IRI, immunoreactive insulin; HOMA, homeostasis model assessment; hsCRP, high-sensitivity C reactive protein; NT-pro BNP, N-terminal pro b-type natriuretic peptide; CPR, C-peptide immunoreactivity; CT, computed tomography; BSA, body surface area.